PRAME
Summary: This gene encodes an antigen that is preferentially expressed in human melanomas and that is recognized by cytolytic T lymphocytes. It is not expressed in normal tissues, except testis. The encoded protein acts as a repressor of retinoic acid receptor, and likely confers a growth advantage to cancer cells via this function. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2014].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| preferentially expressed antigen in melanoma | MIM:606021 | Ensembl:ENSG00000185686 | HGNC:HGNC:9336 | PA33698 | 22q11.22 |
GO terms in PRAME
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | IPI | GO:0005515 | protein binding |
| MF | IDA | GO:0042974 | retinoic acid receptor binding |
| BP | IEA | GO:0006351 | transcription, DNA-templated |
| BP | IEA | GO:0006915 | apoptotic process |
| BP | IDA | GO:0008284 | positive regulation of cell proliferation |
| BP | IEA | GO:0030154 | cell differentiation |
| BP | IEA | GO:0040008 | regulation of growth |
| BP | IDA | GO:0043066 | negative regulation of apoptotic process |
| BP | IDA | GO:0045596 | negative regulation of cell differentiation |
| BP | IDA | GO:0045892 | negative regulation of transcription, DNA-templated |
| BP | IDA | GO:0048387 | negative regulation of retinoic acid receptor signaling pathway |
| CC | IEA | GO:0005634 | nucleus |
| CC | IEA | GO:0005886 | plasma membrane |
Gene expression in normal tissue: PRAME
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in PRAME
| Database | Pathway ID | Pathway Des. |
|---|
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD126 | Tipifarnib | 2 |
| iGMDRD425 | ERASTIN | 4 |
| iGMDRD670 | ML 210 | 1 |
| iGMDRD483 | SCH-529074 | 1 |
| iGMDRD639 | YK 4-279 | 1 |
| iGMDRD316 | N9-Isopropyl-olomoucine | 1 |
| iGMDRD793 | BEC (hydrochloride) | 1 |
| iGMDRD61 | Kinetin riboside | 5 |
| iGMDRD152 | 179324-69-7 | 8 |
| iGMDRD394 | BX-795 | 3 |
| iGMDRD513 | BML-259 | 3 |
| iGMDRD474 | Avrainvillamide | 4 |
| iGMDRD260 | FQI-2 | 1 |
| iGMDRD52 | Rotenone | 2 |
| iGMDRD187 | BRD9876 | 2 |
| iGMDRD188 | Piperlongumine | 9 |
| iGMDRD74 | Idarubicin | 5 |
| iGMDRD730 | Kahalalide F | 1 |
| iGMDRD780 | PP-30 | 4 |
| iGMDRD369 | TGX-115 | 2 |
| iGMDRD64 | Parbendazole | 2 |
| iGMDRD23 | Gossypol | 8 |
| iGMDRD524 | ISX-9 | 2 |
| iGMDRD48 | Dexamethasone | 2 |
| iGMDRD330 | BRD4132 | 3 |
| iGMDRD248 | BRD4354 | 3 |
| iGMDRD150 | RITA | 3 |
| iGMDRD560 | MK-2206 | 3 |
| iGMDRD532 | Olaparib | 3 |
| iGMDRD523 | Cyanoquinoline, 11 | 5 |
| iGMDRD79 | Gemcitabine | 3 |
| iGMDRD698 | Neratinib | 1 |
| iGMDRD237 | ABT-751 | 3 |
| iGMDRD123 | Isoevodiamine | 5 |
| iGMDRD945 | ML214 | 6 |
| iGMDRD883 | CIL55A | 1 |
| iGMDRD103 | SN-38 | 1 |
| iGMDRD158 | NSC141540 | 2 |
| iGMDRD137 | Indisulam | 1 |
| iGMDRD202 | Curcumin | 1 |
| iGMDRD105 | Triptolide | 1 |
| iGMDRD705 | Nakiterpiosin | 3 |
| iGMDRD77 | Itraconazole | 1 |
| iGMDRD213 | SMR000068650 | 3 |
| iGMDRD286 | Nsc 632839 | 5 |
| iGMDRD662 | JQ-1 | 3 |
| iGMDRD329 | Merck60 | 2 |
| iGMDRD599 | Salermide | 1 |
| iGMDRD387 | CHIR-99021 | 3 |
| iGMDRD579 | PF750 | 1 |
| iGMDRD772 | BRD4770 | 2 |
| iGMDRD1008 | SR-II-138A | 2 |
| iGMDRD144 | NSC95397 | 4 |
| iGMDRD446 | LY 2183240 | 3 |
| iGMDRD193 | Fqi1 | 2 |
| iGMDRD163 | all trans Retinoic Acid | 2 |
| iGMDRD138 | PX 12 | 3 |
| iGMDRD885 | Compound 110 | 2 |
| iGMDRD318 | PAC-1 | 3 |
| iGMDRD870 | BRD63610 | 5 |
| iGMDRD100 | Zebularine | 2 |
| iGMDRD887 | Compound 23 citrate | 1 |
| iGMDRD577 | BIX01294 | 4 |
| iGMDRD562 | Navitoclax | 5 |
| iGMDRD690 | PRIMA-1MET | 5 |
| iGMDRD60 | Quinoclamine | 3 |
| iGMDRD598 | QS-11 | 1 |
| iGMDRD268 | Cerulenin | 2 |
| iGMDRD451 | Serdemetan | 6 |
| iGMDRD486 | Tosedostat | 1 |
| iGMDRD307 | Manumycin A | 1 |
| iGMDRD512 | nutlin 3 | 4 |
| iGMDRD607 | Ubistatin B | 2 |
| iGMDRD701 | NVP-AUY922 | 1 |
| iGMDRD901 | ELCPK | 1 |
| iGMDRD211 | (1S,3R)-RSL3 | 3 |
| iGMDRD177 | Teniposide | 2 |
| iGMDRD132 | (-)-gallocatechin-3-O-gallate | 4 |
| iGMDRD220 | fumonisin B1 | 2 |
| iGMDRD886 | Compound 1541A | 11 |
| iGMDRD300 | Tozasertib | 2 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in PRAME
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.